Home › Breast Cancer › Nebraska › Omaha
Breast Cancer clinical trials in Omaha, NE
23 studies for Breast Cancer are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecruitingPhase 2
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RecruitingPhase 1/2
- Nebraska Cancer Specialists, Omaha
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RecruitingPhase 3
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Nebraska Medical Center Buffet Cancer Center, Omaha
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecruitingPhase 3
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- Nebraska Medicine-Village Pointe, Omaha
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- and 3 more
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
RecruitingPhase 3
- Research Site, Omaha
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
RecruitingPhase 1
- Nebraska Cancer Specialists, Omaha
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RecruitingPhase 2
- Nebraska Cancer Specialists, Omaha
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RecruitingPhase 3
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Integrated Cancer Repository for Cancer Research
RecruitingObservational studyHealthy volunteers welcome
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- and 1 more
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
RecruitingPhase 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
ERAS Protocols in Breast Conserving Surgery
Recruiting
- University of Nebraska Medical Center, Omaha
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecruitingPhase 3
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi away
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Omaha
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
RecruitingPhase 1
- Biotheryx Investigative Site, Omaha
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RecruitingObservational study
- Nebraska Methodist, Omaha
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY134 studies
- Houston, TX126 studies
- Boston, MA110 studies
- Nashville, TN79 studies
- Los Angeles, CA71 studies
- Edison, NJ69 studies
- St. Louis, MO64 studies
- Durham, NC63 studies
- Queens, NY63 studies
- Chicago, IL58 studies
- Philadelphia, PA56 studies
- Dallas, TX54 studies
Other studies in Omaha
- Prostate Cancer28 studies
- Non-Small Cell Lung Cancer25 studies
- Cancer (all types)19 studies
- Colorectal Cancer19 studies
- Multiple Myeloma16 studies
- Ovarian Cancer15 studies
- Pancreatic Cancer14 studies
- Metastatic Cancer14 studies
- Non-Hodgkin Lymphoma14 studies
- Heart Failure13 studies
- Lung Cancer13 studies
- Head and Neck Squamous Cell Carcinoma13 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.